What Is BMY Fair Value?
Bristol-Myers Squibb Company (BMY) fair value estimate using multiple valuation models, updated daily.
As of October 31, 2026, Bristol-Myers Squibb Company (BMY) has a composite fair value estimate of $43.91 based on four valuation models: DCF (35% weight), Graham Number (25% weight), PEG (25% weight), and DDM (15% weight). The current market price is $62.48, suggesting the stock is overvalued by 29.7%.
Data as of October 31, 2026 (today)
Composite Fair Value
Overvalued4 of 4 models$43.91
vs. current price of $62.48(-29.7%)
How Is BMY Fair Value Calculated?
Four independent models estimate what BMY is worth. Each uses different inputs and assumptions. The composite blends them by weight.
BMY Intrinsic Value
Forward-looking models based on future cash flows
DCF (Discounted Cash Flow)
35% weightEstimates how much cash the company will generate over the next 10 years, then calculates what all that future cash is worth in today's dollars. Includes a 15% safety cushion. Try the standalone DCF calculator →
$33.02
-47.2%Overvalued
Inputs used
DDM (Dividend Discount Model)
15% weightIf a company pays you dividends, this model asks: how much are all those future dividend payments worth today? Only works for stocks that pay dividends. Try the intrinsic value calculator →
$32.13
-48.6%Overvalued
Inputs used
BMY Fair Value
Current fundamentals: earnings, assets, and growth rate
Graham Number (Value Investing)
25% weightCreated by legendary investor Benjamin Graham. It looks at two things: how much the company earns (EPS) and what its assets are worth (Book Value), then calculates the maximum price a careful investor should pay. Try the fair value calculator →
$36.54
-41.5%Overvalued
Inputs used
PEG (Price/Earnings to Growth)
25% weightChecks if you're paying a fair price for the company's growth. A fast-growing company deserves a higher price than a slow one. This model finds the right price based on how fast earnings are growing.
$65.41
+4.7%Fair Value
Inputs used
What If You Change the Assumptions?
Drag the sliders to test different scenarios. Tap the ? buttons to learn what each input means.
Your DCF Fair Value
Current price $62.48 is 47.2% above this estimate
View 10-year cash flow projections
| Year | Projected FCF (Free Cash Flow) | Present Value |
|---|---|---|
| Year 1 | $5.49B | $4.99B |
| Year 2 | $5.70B | $4.71B |
| Year 3 | $5.92B | $4.44B |
| Year 4 | $6.14B | $4.19B |
| Year 5 | $6.37B | $3.96B |
| Year 6 | $6.61B | $3.73B |
| Year 7 | $6.86B | $3.52B |
| Year 8 | $7.12B | $3.32B |
| Year 9 | $7.39B | $3.14B |
| Year 10 | $7.67B | $2.96B |
| Terminal Value | $104.89B | $40.44B |
What Are BMY's Key Financial Metrics?
Earnings & Growth
Current Price
$62.48
EPS (TTM)
$4.54
Forward P/E
9.4
Profit Margin
18.5%
Cash & Balance Sheet
Free Cash Flow
0
EBITDA
18.8B
Book Value
$9.07
Total Debt
0
What Do Analysts Say About BMY?
Low
$40.00
Average
$65.39
High
$80.00
Upside
+4.7%
BMY Fair Value FAQ
What is the fair value of BMY?
Based on our composite model (DCF 35%, Graham 25%, PEG 25%, DDM 15%), BMY's estimated fair value is $43.91. The stock is currently trading at $62.48, which makes it overvalued by our analysis.
How is BMY's fair value calculated?
We use four valuation methods: Discounted Cash Flow (DCF), Graham Number, PEG-based Fair Value, and Dividend Discount Model (for dividend-paying stocks). The composite score weights DCF at 35%, Graham and PEG at 25% each, and DDM at 15%. When a model can't be applied, its weight is redistributed proportionally.
Is BMY overvalued or undervalued?
Based on our analysis, BMY is overvalued. The current price of $62.48 is 29.7% above our estimated fair value of $43.91.
What do Wall Street analysts say about BMY?
23 analysts cover Bristol-Myers Squibb Company with a consensus rating of "Buy." The average price target is $65.39, ranging from $40.00 to $80.00. This implies 4.7% upside from the current price.